semaglutide prediabetes progression to diabetes trial Effect of 2.4 mg once weekly on 10‐year type 2 risk in adults with overweight or obesity - Wilkinson - 2023 - Obesity Once-Weekly Semaglutide 2.4 mg Improved

From a clinical perspective, it is relevant to address gut microbiome composition as this is a foundational component of human physiology

From my understanding, pharmacokinetically, this drug is active and highly stable at low pHs

How clinicians read investigational obesity data When clinicians review early or mid-stage obesity data, they usually look at more than the headline weight-loss result

Melanotan I is selective for MC1R and studied mainly for pigmentation and photoprotection, while Melanotan II is less selective, also hitting MC4R, and is studied for additional libido and appetite pathways

Melanie Avalon I love 11-11